A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59 (R) Adjuvant
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2019
At a glance
- Drugs Influenza A virus H7N9 vaccine Seqirus (Primary) ; MF 59
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 08 Nov 2018 Status changed from not yet recruiting to recruiting.
- 01 Nov 2018 Planned initiation date changed from 29 Oct 2018 to 22 Nov 2018.
- 11 Oct 2018 Planned initiation date changed from 8 Oct 2018 to 29 Oct 2018.